Rosen Law Firm Investigating Potential Securities Claims Against Aldeyra Therapeutics

Investors who suffered losses in Aldeyra Therapeutics stock are encouraged to contact the firm about their rights.

Mar. 22, 2026 at 7:53pm

Got story updates? Submit your updates here. ›

The Rosen Law Firm, a global investor rights law firm, has announced an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX). The investigation follows Aldeyra's announcement that it received a Complete Response Letter from the FDA regarding its New Drug Application for reproxalap, stating a lack of substantial evidence of efficacy for the treatment of dry eye disease.

Why it matters

This news caused Aldeyra's stock price to plummet 70.7%, raising concerns about potential misleading information provided to investors. The Rosen Law Firm is preparing a class action lawsuit to recover losses for affected shareholders.

The details

On March 17, 2026, Aldeyra filed an 8-K with the SEC announcing it had received a Complete Response Letter from the FDA regarding its NDA for reproxalap. The FDA stated there was a 'lack of substantial evidence' that the drug would have the claimed effect, and that the 'totality of evidence from the completed clinical trials does not support the effectiveness of the product.' This news caused Aldeyra's stock price to fall $2.99 per share, or 70.7%, to close at $1.24 per share.

  • On March 17, 2026, Aldeyra filed an 8-K with the SEC announcing the FDA's Complete Response Letter.

The players

Aldeyra Therapeutics, Inc.

A biopharmaceutical company focused on the development of therapies for the treatment of dry eye disease and other inflammatory conditions.

U.S. Food and Drug Administration (FDA)

The federal agency responsible for regulating and supervising the safety of food, drugs, and other products in the United States.

The Rosen Law Firm, P.A.

A global investor rights law firm that is investigating potential securities claims on behalf of Aldeyra Therapeutics shareholders.

Got photos? Submit your photos here. ›

What they’re saying

“We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel.”

— Laurence Rosen, Founding Partner, The Rosen Law Firm

What’s next

The Rosen Law Firm is preparing a class action lawsuit to recover losses for investors who purchased Aldeyra Therapeutics securities.

The takeaway

This investigation highlights the importance for investors to carefully scrutinize information provided by public companies, as misleading statements can lead to significant losses. The Rosen Law Firm's class action aims to hold Aldeyra accountable and recover damages for affected shareholders.